. 2015 May 13;34(1):42. doi: 10.1186/s13046-015-0162-5

Table 2.

Numerical and percentage distribution of ligand/VEGFR-2 and VEGFR-2/pVEGFR-2 co-expression in the tumor cells

	N0/M0	N+	M+
	n (%)	n (%)	n (%)
Tumor center
VEGF-C+/VEGFR-2+	22/14 (64)	16/9 (56)	14/7 (50)
VEGF-D+/VEGFR-2+	22/16 (73)	12/10 (83)	11/7 (64)
VEGFR-2+/pVEGFR-2^Tyr1175+	19/14 (74)	13/11 (85)	12/5 (42)
VEGFR-2+/pVEGFR-2^Tyr1214+	19/17 (89)	13/10 (77)	13/11 (85)
Tumor budding
VEGF-C+/VEGFR-2+	16/12 (75)	10/7 (70)	10/8 (80)
VEGF-D+/ VEGFR-2+	16/13 (81)	10/8 (80)	13/8 (62)
VEGFR-2+/pVEGFR-2^Tyr1175+	16/11 (69)	10/8 (80)	12/7 (58)
VEGFR-2+/pVEGFR-2^Tyr1214+	16/16 (100)	10/9 (90)	13/13 (100)

n: total number of ligand positive cases/total number of ligand positive cases with concomitant VEGFR-2 positivity or total number of VEGFR-2 positive cases/total number of VEGFR-2 positive cases with concomitant pVEGFR-2 positivity. There were no significant differences between the groups